GreenLight Biosciences, Samsung Biologics Partner to Advance New RNA Covid Vax

GreenLight Biosciences, a Biotechnology company dedicated to making ribonucleic acid ( RNA ) products affordable and accessible for human health and agriculture, and Samsung Biologics, a global CDMO providing fully integrated end-to-end contract development and manufacturing services, have entered a partnership agreement in which Samsung Biologics will manufacture GreenLight’s messenger RNA COVID-19 Vaccine candidate at commercial scale.
The partnership aims to accelerate the production of GreenLight’s COVID-19 vaccine candidate for Phase III   Clinical Trials and, subject to regulatory approval, commercial sales. The collaboration with Samsung will leverage GreenLight’s existing manufacturing process, with Technology Transfer from GreenLight to Samsung starting immediately.
“We are delighted to partner with Samsung to manufacture messenger RNA for our Covid vaccine trial. There is an urgent need to develop vaccines for the whole world,” said GreenLight CEO Andrey Zarur. “Our vaccine trial will open the way to make vaccines that are available to everybody, not just citizens of developed countries.”
“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA COVID-19 vaccine candidate to better serve patients in lower income countries,” said John Rim, CEO of Samsung Biologics. “This collaboration demonstrates a major milestone for Samsung Biologics as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production from Drug Substance ( DS ) to Aseptic Fill Finish (DP) to commercial release, all from a single site. At this time of urgent global demand, we will strive for seamless service across our biomanufacturing network to fight the COVID pandemic and in turn, help make progress towards Korea's vaccine hub goal.”
Samsung Biologics has been proactive in accommodating client needs in the biopharma CDMO landscape, including its plans to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.